Journals / Hacettepe Üniversitesi Eczacılık Fakültesi Dergisi / 2023 / Cilt: 43 Sayı: 1

An Evaluation of Amyotrophic Lateral Sclerosis and Current Situation in Its Treatment

Amyotrofik Lateral Skleroz Patofizyolojisi ve Tedavi Yaklaşımları

Pages
50–69
Publication Date
2023-03-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this study, the pathogenesis of ALS disease, its treatment, and the development of the treatment were included, the treatment potentials of drugs were examined and an evaluation was prepared to guide future studies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:ALS, which is diagnosed in 1500 to 4500 people every year in our country, is known as a fatal neurodegenerative disease manifested by progressive loss of muscle function.
📊
Key Findings & Data:Glutamate excitotoxicity and genetic factors are seen as the most important factors in the pathogenesis of this disease, where individuals cannot even meet their own basic needs day by day.
💡
Conclusion & Impact:In this study, the pathogenesis of ALS disease, its treatment, and the development of the treatment were included, the treatment potentials of drugs were examined and an evaluation was prepared to guide future studies.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Amyotrofik lateral skleroz · nörodejenerasyon · patogenez

Abstract

ALS, which is diagnosed in 1500 to 4500 people every year in our country, is known as a fatal neurodegenerative disease manifested by progressive loss of muscle function. Glutamate excitotoxicity and genetic factors are seen as the most important factors in the pathogenesis of this disease, where individuals cannot even meet their own basic needs day by day. Although research on a lot of symptomatic and therapeutic drugs continues, only FDA-approved riluzole and edaravone are included in the treatment protocol. In addition, cell-based therapies and phytotherapy have also been used in both the prevention and treatment of the disease, the improvement of the symptoms, and the improvement of the quality of life of the patients. In this study, the pathogenesis of ALS disease, its treatment, and the development of the treatment were included, the treatment potentials of drugs were examined and an evaluation was prepared to guide future studies.

Özet

Ülkemizde her yıl 1500 ile 4500 kişiye tanısı konulan ALS ilerleyici kas fonksiyon kaybı ile kendini gösteren ölümcül bir nörodejeneratif hastalık olarak bilinmektedir. Günden güne bireylerin kendi temel ihtiyaçlarını dahi tek başına karşılayamadığı bu hastalığın patogenezinde glutamat eksitotoksisitesi ve genetik faktörler en önemli etmenler olarak görülmektedir. Birçok semptomatik ve tedaviye yönelik ilaç araştırmaları devam etse de tedavi protokolünde yalnızca FDA onaylı riluzol ve edaravon yer almaktadır. Bunun yanı sıra hem hastalığın önlenmesi ve tedavi edilmesi hem de semptomların iyileştirilmesi ve hastaların yaşam kalitesinin arttırılmasında hücre bazlı tedavilerden ve fitoterapiden de yararlanılmaktadır. Bu çalışma ile ALS hastalığının patogenezine, tedavisine ve tedavisindeki gelişmelere yer verilerek ilaçların tedavi potansiyelleri incelenmiş ve yeni çalışmalara yol göstermesi amacıyla bir değerlendirme hazırlanmıştır.

🔖

Cite This Article

YILDIRIM, Z., TOKTAŞ, D. N., DEMİR, Ö., GÜL, Z., UTSUKARÇİ, B. Ş. (2023). An Evaluation of Amyotrophic Lateral Sclerosis and Current Situation in Its Treatment. Hacettepe Üniversitesi Eczacılık Fakültesi Dergisi, Cilt: 43 Sayı: 1, 50–69. https://ajindex.com/articles/906526

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Longinetti E, Wallin AR, Samuelson K, Press Y, Zachau A, Ronnevi LO, Kierkegaard M, Andersen PM, Hillert J, Fang F, Ingree C: The Swedish Motor Neuron Disease Quality Registry. Amyotrophic Lateral Sclerosis and Frontotemporal Degener 2018, 19: 528-537
  2. Palese F, Sartori A, Veriello L, Ros S, Passadore P, Manganotti P, Barbone F, Pisa FE: Epidemiology of Amyotrophic Lateral Sclerosis in Friuli-Venezia Giulia, North-Eastern Italy, 2002-2014: A Retrospective Population Based Study. Amyotrophic Lateral Sclerosis Frontotemporal Degener 2019, 20: 90-99
  3. Marangoz AD, Erdoğan Ç: Amyotrofik Lateral Skleroz (ALS) Hastalığının Patogenezi. Pamukkale Tıp Dergisi 2020, 13 (2): 477-484
  4. Alankaya N: Amyotrofik lateral skleroz ve bakım. Türkiye Klinikleri Journal of Internal Medicine Nursing-Special Topics 2016, 2 (2): 73-9
  5. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC: Amyotrophic Lateral Sclerosis. Lancet 2011, 377: 942–955
  6. Nelson LM, Topol B, Kaye W, Williamson D, Horton DK, Mehta P, Wagner T: Estimation of The Prevalence of Amyotrophic Lateral Sclerosis in The United States Using National Administrative Healthcare Data From 2002 to 2004 and Capture-Recapture Methodology. Neuroepidemiology 2018, 51: 149-157
  7. Jun KY, Park J, Oh KW, Kim EM, Bae JS, Kim I, Kim SH: Epidemiology of ALS in Korea Using Nationwide Big Data. Journal of Neurology Neurosurgery and Psychiatry 2019, 90 (4): 395-403
  8. Logroscino G, Traynor BJ, Hardiman O, Chiò A, Mitchell D, Swingler RJ, Millul A, Benn E, Beghi E: Incidence of Amyotrophic Lateral Sclerosis in Europe. Journal of Neurology Neurosurgery and Psychiatry 2010, 81: 385-390
  9. Ludolph A, Drory V, Hardiman O, Nakano I, Ravits J, Robberecht W, Shefner J: A Revision of The El Escorial Criteria. Informa Healthcare 2015, DOI: 10.3109/21678421.2015.1049183
  10. Hardiman O, Van Den Berg LH, Kiernan MC: Clinical diagnosis and management of amyotrophic lateral sclerosis. Nature Reviews Neurology 2011, 7 (11): 639-649
  11. Miller RG, Munsat TL, Swash M, Brooks BR: Consensus Guidelines for The Design and İmplementation of Clinical Trials in ALS, Journal of The Neurological Sciences 1992, 169: 2-12
  12. Daube JR: Elektrodiagnostic studies in amyotrophic lateral sclerosis and other motor neuron disorders. Muscle & Nerve 2000, 23 (10): 1488-1502
  13. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O: Amyotrophic lateral sclerosis mimic syndromes. Archives of Neurology 2000, 57(1):109-